

## PATIENT:

Full name: \_\_\_\_\_ Nationality: \_\_\_\_\_

Address: \_\_\_\_\_ Date of birth: \_\_\_\_\_

Suburb/City: \_\_\_\_\_  Male  Female

Country: \_\_\_\_\_

## THE PATIENT IDENTIFIED ABOVE IS RECEIVING TREATMENT FOR:

- |                                                        |                                                                   |
|--------------------------------------------------------|-------------------------------------------------------------------|
| <input type="checkbox"/> Rheumatoid arthritis          | <input type="checkbox"/> Plaque psoriasis                         |
| <input type="checkbox"/> Juvenile idiopathic arthritis | <input type="checkbox"/> Paediatric plaque psoriasis              |
| <input type="checkbox"/> Psoriatic arthritis           | <input type="checkbox"/> Non-radiographic axial spondyloarthritis |
| <input type="checkbox"/> Ankylosing spondylitis        |                                                                   |

## UNDER THE MEDICAL CARE OF:

Rheumatologist / Dermatologist: \_\_\_\_\_

Hospital/Practice: \_\_\_\_\_

## PATIENT USES:

- |                                                                                     |                                                           |
|-------------------------------------------------------------------------------------|-----------------------------------------------------------|
| <input type="checkbox"/> Etanercept (ENBREL®) 50mg Pre-filled Auto-injector pen     | <input type="checkbox"/> Subcutaneously (sc) once weekly  |
| <input type="checkbox"/> Etanercept (ENBREL®) 25mg Pre-filled Auto-injector pen     | <input type="checkbox"/> Subcutaneously (sc) twice weekly |
| <input type="checkbox"/> Etanercept (ENBREL®) 50mg Pre-filled syringe               |                                                           |
| <input type="checkbox"/> Etanercept (ENBREL®) 25 mg powder and solvent for solution |                                                           |



This patient self-administers their medication and therefore needs to carry packs with pre-filled ENBREL pens or syringes, or packs with syringes, needles and vials with ENBREL powder (see picture above) in his/her hand luggage.

It's important to store ENBREL properly at all times. This means storing ENBREL in the original packaging in a refrigerator where the temperature stays between 2°C and 8°C. If it is not possible to store ENBREL under refrigerator conditions, such as when travelling, ENBREL may be stored out of the refrigerator (to a maximum of 25°C) for up to 4 weeks. On such occasions, it is suggested that you take note of the date it was taken out of refrigeration, as well as the date it should be used by, note ENBREL must be used within 4 weeks of the date it was taken out of refrigeration. Do not use ENBREL if it has been exposed to high temperatures or if it has been out of the refrigerator for more than 4 weeks. You should always protect ENBREL from light, sources of heat, and humidity until you are ready to use it, and keep out of the reach of children. To request Refrigeration-Removal Date stickers, please order via 0800 ENBREL (0800 362 735). To assist you with travel, an ENBREL travel wallet is available. You can keep unused auto-injectors, pre-filled syringes, or unopened vials in your ENBREL travel wallet. You can request an ENBREL travel wallet from your doctor or nurse, or by contacting 0800 ENBREL (0800 362 735).

Refer overleaf for brief product details.

\_\_\_\_\_  
(Doctor's signature)

\_\_\_\_\_  
(Doctor's stamp)

**25 mg powder for injection plus diluent; 25 mg solution for injection (Auto-injector) and 50 mg solution for injection (pre-filled syringe and Auto-injector)**

ENBREL (etanercept) is a prescription medicine containing 25 mg or 50 mg of etanercept.

It is used to treat rheumatoid arthritis, juvenile idiopathic arthritis (JIA), psoriatic arthritis in adults, ankylosing spondylitis in adults, non-radiographic axial spondyloarthritis in adults and plaque psoriasis in children and adults. Enbrel has risks and benefits. Use strictly as directed. Consult your doctor to see if ENBREL is right for you. If symptoms continue or you have side effects, see your doctor, pharmacist or healthcare professional. Do not take ENBREL if you are allergic to any of its ingredients, if you have a serious infection, have a blood infection or are at risk of one, or are currently taking an interleukin-1 antagonist, such as Kineret. Caution is needed if you are being treated for diabetes, are taking Orencia, Endoxan or Salazopyrin, have heart failure, cancer, multiple sclerosis or inflammation of the nerves of the eyes, during vaccination or in children who have not completed their immunisation program, if you are pregnant or planning to become pregnant or are breastfeeding. Tell your doctor if you are taking any other medicines. Common side effects: injection site reactions, allergic reactions, infections. Tell your doctor immediately if you experience any of the following as these may be signs of serious side effects: tiredness, headaches, shortness of breath, stomach pain and/or diarrhoea, dizziness, nose bleeds, paleness, bruising more frequently, skin rash, blisters or ulcers on your skin, seizures, numbness or tingling in your body, weakness in your limbs, swelling of your face, lips, tongue, arms or legs; itchiness and hives. ENBREL is fully funded on special authority. A pharmacy charge and normal doctor's fees apply. Further information on ENBREL and the Consumer Medicine Information is available from [www.medsafe.govt.nz](http://www.medsafe.govt.nz) or Pfizer New Zealand Ltd, Auckland, [www.pfizer.co.nz](http://www.pfizer.co.nz), Ph. 0800 736 363. Pfizer New Zealand Limited, Auckland. V10321  
PZR0623 PP-ENB-NZL-0270-May 2023. TAPS DA 2257EL.

Enbrel® is a Registered Trademark. © Pfizer 2023